COVID-19: a primer for the rheumatologist: management of patients and care settings.
Curr Opin Rheumatol
; 32(5): 429-433, 2020 09.
Article
in English
| MEDLINE | ID: covidwho-704674
ABSTRACT
PURPOSE OF REVIEW There are currently many unanswered questions surrounding the management of patients with immune-mediated inflammatory diseases during the COVID-19 pandemic and several 'rapid' guidelines have been released, although are subject to be updated and changed in the near future. The purpose of this review is to discuss the approach to management of patients with immune-mediated diseases during the COVID-19 pandemic. RECENT FINDINGS:
At present, there is little evidence to suggest an increased risk of COVID-19 infection or its complications in patients with immune-mediated diseases or associated with conventional or biologic disease modifying antirheumatic drugs; however, glucocorticoid use does appear to have negative associations.SUMMARY:
Currently, conventional and biologic disease modifying antirheumatic drugs can be continued in the absence of SARS-CoV-2 exposure. In the case of exposure, with the exception of hydroxyhcloroquine and sulfasalazine, immunosuppression should be held for 2 weeks. Our recommendations and the guidelines we discuss here are based on C-level recommendations but help provide a framework for how to counsel our patients during this pandemic.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Rheumatic Diseases
/
Immunosuppression Therapy
/
Clinical Competence
/
Coronavirus Infections
/
Antirheumatic Agents
/
Rheumatologists
/
Betacoronavirus
Type of study:
Observational study
/
Prognostic study
Topics:
Long Covid
Limits:
Humans
Language:
English
Journal:
Curr Opin Rheumatol
Journal subject:
Rheumatology
Year:
2020
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS